Targets › ANO1
2 programs from 2 companies in 2 trials: 2 Phase 2; Other, Gastroenterology; next expected readout Dec 2026.
Calcium-activated chloride channel (CaCC). Plays a role in transepithelial anion transport and smooth muscle contraction. (UniProt, Q5XXA6)
Open in Phaseline: the race on ANO1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Napo Pharmaceuticals | Crofelemer Cystic fibrosis transmembrane conductance regulator inhibitor; Anoctamin-1 blocker | CFTR, ANO1 | Phase 2 | Microvillus Inclusion Disease | Dec 2026 |
| Napo Therapeutics | Crofelemer Cystic fibrosis transmembrane conductance regulator inhibitor; Anoctamin-1 blocker | CFTR, ANO1 | Phase 2 | Short Bowel Syndrome | Mar 2027 |
Microvillus Inclusion Disease (1) Short Bowel Syndrome (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.